Skip to main content

Business Wire India

academics

 

Clinical research courses

  • (Business Wire India; 5th June, 2014); A new report by the Advanced Medical Technology Association (AdvaMed) demonstrates the lack of awareness among consumers about medical devices.
    The findings of a survey of 1300 Indians from across 17 states conducted by AdvaMed – an association of medical device manufacturers leading the effort to provide medical technology to the world – reveals that although an overwhelming 72% of respondents use medical devices, 89% say that they do not know enough about them.

  • (Business Wire India; 5th June, 2014); Kinetic Concepts, Inc. announced today that a new study, published in the International Wound Journal, showed the Prevena™ Incision Management System used over closed incisions for the first six to seven days reported a significantly lower infection rate than conventional dressings in patients undergoing cardiac surgery via median sternotomy. Post-sternotomy wound infection is a serious, potentially fatal complication of cardiac surgery which often requires additional surgery, and is associated with significantly increased health care costs.

  • (Business Wire India; 3rd June, 2014); Bristol-Myers Squibb and Syngene International, India’s largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.
    Since 2007, Bristol-Myers Squibb has been working with Syngene and its corporate parent, Biocon Ltd., to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development at the Biocon Bristol-Myers Squibb Research Center (BBRC) in Bangalore.

  • (Business Wire India; 19th May, 2014); Ferring Pharmaceuticals marks World IBD Day (May 19th) with the launch of Guts4life (guts4life.com), a new interactive website with information, support and inspiration for people concerned with Crohn’s disease and ulcerative colitis, conditions known as inflammatory bowel diseases (IBD). IBD describes a range of chronic diseases of the gastrointestinal system characterised by intermittent flares with debilitating symptoms that can affect a patient’s quality of life and lead to emotional distress and social isolation. Guts4life was designed together with IBD patients to provide support and encouragement throughout the IBD journey—from bowel symptom worries, to diagnosis, through managing and living with IBD.

    (adsbygoogle = window.adsbygoogle || []).push({});
  • Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area

    (Business Wire India; 13th May, 2014); Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, and Orion Corporation (Orion), the largest pharmaceutical company in Finland, today announced a path breaking drug discovery collaboration to discover small molecule inhibitors in neuroscience therapeutic area. The research deal is aimed at developing drug that can benefit large population of people with unmet needs in the pain management area.

  • New Study Suggests Desmopressin Melt Improves Sleep Patterns and Psychological Functioning of Bedwetting Children

    (Business Wire India; 12th May, 2014); New data has shown that treatment with melt-in-the-mouth desmopressin (MINIRIN® Melt)* improved sleep patterns and psychological functioning (including attention problems and memory) in children with nocturnal enuresis (bedwetting). The negative impact of bedwetting on children’s neuropsychological functioning (e.g. anxiety and social self-esteem problems) was also shown. The data from a study by researchers at the University Hospital Ghent, Belgium was presented at the 25th annual congress of the European Society for Paediatric Urology (ESPU) in Innsbruck, Austria.

  • ElectroCore: Two separate studies on the treatment of migraine headache with non invasive vagus nerve stimulation are being presented at the American Association of Neurology (AAN) meeting in Philadelphia

    (1st May, 2014); At the AAN meeting in Philadelphia, two separate studies showed that electroCore’s non invasive vagus nerve stimulation (nVNS) therapy was effective in helping patients with different types of migraine. The first poster presentation, on April 28th, found that two hours after treatment with electroCore’s nVNS therapy patients who had both chronic migraine and medication overuse headache were pain free in 33% of attacks while significant pain relief (mild or no pain) was noted in 50% of attacks. In the second poster presented on May1st it was found that 45 % of patients, with migraine without aura, were pain free within 30 minutes of just one dose of nVNS therapy.

  • Shiseido Opens Research Facility Dedicated to Hair Regeneration

    Shiseido Co., Ltd. announces plans to open the Shiseido Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center, located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan, will centralize research and development on hair regenerative medicine with an aim toward commercialization.

  • Malignant brain tumor is new medical concern due to wi-fi and Cell Phone use

    New studies escalate medical concerns about glioma (a malignant brain tumor) from cell phone use. The BioInitiative Working Group (BWG) noted that evidence for health risk from wireless technology is growing stronger and require immediate action. The Group released a mid-year update covering new science studies from 2012 to 2014.

Subscribe to Business Wire India